fluidIQ pitches breathing tech at ATS innovation summit

By AI, Created 4:20 PM UTC, May 22, 2026, /AGP/ – fluidIQ co-founder Teresa Barnes presented the company’s breathing and resuscitation technology at the American Thoracic Society Respiratory Innovation Summit in Orlando this week. The appearance put fluidIQ in front of investors, clinicians and researchers as the company moves toward regulatory clearance.

Why it matters: - fluidIQ used the American Thoracic Society Annual Respiratory Innovation Summit in Orlando to showcase technology aimed at respiratory care and emergency medicine. - The company is preparing to seek regulatory clearance, making investor and clinician exposure at the meeting strategically important. - fluidIQ’s miniature resuscitation devices are designed to run without electricity or batteries, which could matter in emergency and preparedness settings.

What happened: - Teresa Barnes, fluidIQ’s president and co-founder, presented on stage at the Respiratory Innovation Summit this week in Orlando. - fluidIQ was selected as a showcase company for the meeting. - Barnes also presented a poster on fluidIQ’s respiratory technology. - The summit brought together innovators, investors, clinicians and advocacy groups focused on treatments for lung and airway diseases.

The details: - Barnes called the RIS one of the most important audiences for fluidIQ’s innovation. - CEO Matt Vogelhuber said the company valued the chance to speak with investors interested in respiratory innovation as fluidIQ prepares for regulatory submission and its next growth phase. - fluidIQ said the summit also created direct access to researchers interested in its fluidics-based, electricity-free miniature resuscitation technologies. - The company’s adult miniature resuscitator, HOPE inVent™, is designed to replace manual resuscitation tools that fluidIQ describes as cumbersome for responders and risky for patients. - HOPE inVent™ was featured in the NIH Director’s Blog in December 2022. - fluidIQ’s neonatal and adult resuscitators are not cleared by the U.S. Food and Drug Administration and are not for sale in the United States.

Between the lines: - The presentation suggests fluidIQ is trying to build credibility with the respiratory, research and investment communities at the same time. - The company’s emphasis on battery-free, fluidics-based devices positions the technology as a potential alternative to conventional resuscitation tools, but commercialization still depends on regulatory progress. - fluidIQ’s collaborations with major institutions signal a broader effort to validate the technology through research partnerships.

What’s next: - fluidIQ plans to submit technology for regulatory clearance. - The National Institutes of Health Clinical Center researchers received FDA approval on an investigational device exemption for a first-in-human study expected to start this year. - fluidIQ’s collaboration with the University of Texas Medical Branch and its licensing, manufacturing and research collaboration with Intersurgical, Inc. / Pulmodyne continue. - The company’s nearly six-year research collaboration with the NIH Clinical Center also remains active. - fluidIQ said pre-clinical research with HOPE inVent™ was previously published in Science Translational Medicine. - More information is available in fluidIQ’s announcement.

The bottom line: - fluidIQ is using a high-profile respiratory conference to build momentum for its battery-free resuscitation technology as it moves toward regulatory review.